Belladelli Federico, Li Shufeng, Zhang Chiyuan A, Del Giudice Francesco, Basran Satvir, Muncey Wade, Glover Frank, Seranio Nicolas, Fallara Giuseppe, Montorsi Francesco, Salonia Andrea, Eisenberg Michael L
Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy; Department of Urology, School of Medicine, Stanford University, Stanford, CA, USA.
Department of Urology, School of Medicine, Stanford University, Stanford, CA, USA; Department of Dermatology, School of Medicine, Stanford University, Stanford, CA, USA.
Eur Urol Focus. 2024 Jan;10(1):139-145. doi: 10.1016/j.euf.2023.08.005. Epub 2023 Sep 9.
Sleep quality and duration have been investigated for their association with health. Insomnia affects up to one-third of adults and may impact male erectile function. In addition, medical treatments for insomnia (many of which are sedatives) may also affect erectile quality.
To investigate the association of erectile dysfunction (ED) in patients diagnosed with and treated for insomnia.
DESIGN, SETTING, AND PARTICIPANTS: We utilized the IBM MarketScan (2007-2016) Commercial and Medicare Supplemental Databases (v 2.0). Age- and enrollment-matched controls were selected among patients without insomnia diagnosis or treatment.
Cox proportional hazard models were used to estimate the risk of incident ED (ie, diagnosis alone, or diagnosis and treatment with phosphodiesterase-5 inhibitors [PDE5i], intracavernous injection (ICI)/urethral suppositories, and penile prosthesis) after the diagnosis or treatment of insomnia while adjusting for relevant comorbidities.
In total, 539 109 men with an insomnia diagnosis were identified. Of these men, 356 575 were also medically treated for insomnia. The mean (±standard deviation) follow-up times for patients diagnosed with insomnia and those diagnosed with and treated for insomnia were 2.8 ± 1.6 and 3.1 ± 1.8 yr, respectively. Men with insomnia were more commonly smokers and had a higher number of office visits and comorbidities than controls (p < 0.001). On an adjusted analysis, both untreated and treated insomnia were associated with increased risks of ED diagnosis (hazard ratio or HR [95% confidence interval {CI}]: 1.58 [1.54-1.62] and 1.66 [1.64-1.69], respectively; p < 0.001). Similarly, men with treated insomnia had a higher risk of having ED treated with PDE5i (HR [95% CI]: 1.52 [1.49-1.55]; p < 0.001) and ICI (HR [95% CI]: 1.32 [1.14-1.54]; p < 0.001) when compared with controls. A limitation of this study was that a lack of granularity regarding patient clinical characteristics (eg, severity of disease, laboratory data, etc.) is inherent to insurance claims data. In addition, the follow-up was limited and may affect associations at longer time points.
In the current report, a consistent association between insomnia and ED diagnosis was identified. Men diagnosed with insomnia only were found to have a higher risk of developing ED. Moreover, men with pharmacological insomnia treatments were more often prescribed treatments for ED. Given the prevalence of insomnia, future studies are warranted to delineate the association of insomnia and its treatment with erectile function.
Insomnia affects up to one-third of adults and impact male erectile function. Men only diagnosed with insomnia were found to have a higher risk of developing erectile dysfunction (ED). Moreover, men with pharmacological insomnia treatments were more often prescribed treatments for ED.
睡眠质量和时长与健康有关,已有研究对其进行了探讨。失眠影响了多达三分之一的成年人,并可能影响男性的勃起功能。此外,失眠的治疗方法(其中许多是镇静剂)也可能影响勃起质量。
调查患有和接受失眠症治疗的患者勃起功能障碍(ED)的关联。
设计、地点和参与者:我们利用 IBM MarketScan(2007-2016 年)商业和补充医疗保险数据库(v 2.0)。在没有失眠症诊断或治疗的患者中选择了年龄和入组相匹配的对照组。
使用 Cox 比例风险模型估计失眠症诊断或治疗(即单独诊断、单独诊断和使用磷酸二酯酶-5 抑制剂 [PDE5i]、阴茎海绵体内注射 [ICI]/尿道栓剂、阴茎假体治疗)后发生 ED 的风险,同时调整了相关合并症。
共确定了 539109 名患有失眠症的男性。其中,356575 名男性还接受了失眠症的药物治疗。诊断为失眠症和诊断和治疗失眠症的患者的平均(±标准差)随访时间分别为 2.8±1.6 年和 3.1±1.8 年。与对照组相比,患有失眠症的男性更常见吸烟者,就诊次数和合并症更多(p<0.001)。在调整分析中,未经治疗和治疗的失眠症均与 ED 诊断风险增加相关(风险比或 HR [95%置信区间 {CI}]:1.58[1.54-1.62]和 1.66[1.64-1.69];p<0.001)。同样,与对照组相比,接受失眠症治疗的男性使用 PDE5i(HR [95%CI]:1.52[1.49-1.55];p<0.001)和 ICI(HR [95%CI]:1.32[1.14-1.54];p<0.001)治疗 ED 的风险更高。本研究的一个局限性是,保险索赔数据中固有地缺乏关于患者临床特征(例如疾病严重程度、实验室数据等)的详细信息。此外,随访时间有限,可能会影响更长时间点的相关性。
在目前的报告中,确定了失眠症与 ED 诊断之间的一致性关联。仅诊断为失眠症的男性发生 ED 的风险更高。此外,接受药物性失眠治疗的男性更常被开具 ED 治疗药物。鉴于失眠症的普遍性,有必要进行进一步的研究以阐明失眠症及其治疗与勃起功能之间的关系。
失眠症影响了多达三分之一的成年人,并影响男性的勃起功能。仅诊断为失眠症的男性发生勃起功能障碍(ED)的风险更高。此外,接受失眠药物治疗的男性更常被开具 ED 治疗药物。